Humacyte Q3 net loss narrows on lower expenses

Overview

• US biotech firm's Q3 net loss narrowed yr/yr, beating analyst expectations

• Q3 operating income missed analyst expectations

• Symvess Q3 sales more than doubled from prior quarter on expanded hospital adoption

Outlook

• Company expects Q4 2026 Symvess sales to at least double Q3 2026 sales

• Company anticipates adding at least 20 new hospitals in H2 2026

• Company plans to submit sBLA for ATEV in dialysis access to FDA in Nov 2026

Result Drivers

• HOSPITAL ADOPTION - Co said 44% increase in hospitals ordering Symvess drove Q3 sales growth

• COMMERCIAL INITIATIVES - Co attributed sales growth to commercialization initiatives started in early 2026

• R&D EXPENSES - Lower R&D expenses in Q3 due to fewer non-commercial manufacturing runs and program wind-downs

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Humacyte Inc is $1.13, about 147.1% above its November 9 closing price of $0.46

Reuters Recommended Reads

• Nov 9 - Annexon Biosciences Q3 net loss narrows on lower R&D expenses, cash runway extends to 2028

• Nov 9 - Immunome Q3 net loss widens on higher expenses

• Nov 9 - TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)